Related Experiment Video
Updated: Apr 16, 2026
08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
16.8K
Stage-specific prognostic biomarkers in melanoma
Yabin Cheng1, Jing Lu2, Guangdi Chen3
1Department of Dermatology and Skin Science, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
Oncotarget
|March 19, 2015
Summary
This study identifies stage-specific biomarkers for melanoma prognostication. BRAF and MMP2 are useful for early stages, while p27 aids in advanced stages, improving personalized melanoma treatment.
Area of Science:
- Oncology
- Biomarker Research
- Melanoma Staging
Background:
- The American Joint Committee on Cancer (AJCC) staging system is standard for melanoma prognostication.
- Melanomas within the same AJCC stage exhibit variable progression and outcomes.
- Biomarkers are needed to refine risk stratification and personalize treatment for melanoma patients.
Purpose of the Study:
- To evaluate the utility of previously identified prognostic biomarkers (BRAF, MMP2, p27, Dicer, Fbw7, Tip60) for risk stratification within individual AJCC melanoma stages.
- To identify stage-specific biomarkers that enhance the prognostic accuracy of the current AJCC system.
Main Methods:
- Kaplan-Meier survival and Cox proportional multivariate analyses were performed on 254 melanoma patients with known biomarker expression levels.
- The prognostic performance of six biomarkers was assessed to identify optimal candidates for stage-specific application.
- Results were validated using an additional independent cohort of 87 patients and a combined cohort of 341 patients.
Main Results:
- BRAF and MMP2 demonstrated significant prognostic value for AJCC Stages I and II melanoma, respectively (P = 0.010, 0.000).
- p27 emerged as a significant prognostic marker for AJCC Stages III and IV melanoma (P = 0.018, 0.046).
- These findings highlight the potential of stage-specific biomarkers in refining melanoma prognostication.
Conclusions:
- BRAF, MMP2, and p27 serve as effective stage-specific prognostic biomarkers for melanoma.
- These identified biomarkers can aid clinicians in more accurately stratifying melanoma patient risk.
- The findings support the development of personalized therapeutic strategies for melanoma based on stage-specific biomarker profiles.
